X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the partnership, OnKai will apply its AI, models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis clinical program evaluating Aramchol (arachidyl amido cholanoic acid).
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galmed Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 10, 2023
Details:
Arachidyl amido cholanoic acid is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (nonalcoholic steatohepatitis) and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Aramchol (Arachidyl amido cholanoic acid) is a first-in-class, novel synthetic small molecule, a conjugate, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (nonalcoholic steatohepatitis) and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Recent data reinforce the anti-fibrotic activity of Aramchol (arachidyl amido cholanoic acid) previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
New Patents granted by USPTO for low dose composition Aramchol (Arachidyl Amido Cholanoic Acid), including Meglumine Salt currently undergoing phase 3 study for the treatment of fibrosis and modulating gut microbiota.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
Data from first 20 patients from the ARMOR study Open Label Part showing that treatment with Aramchol 300mg BID resulted in clinically significant greater histological improvement in 12 out of 20 (60%) of patients.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
Aramchol meglumine is an improved compound using a salt form of Aramchol that has significantly greater water solubility than the free acid and an NCE patent protection valid until December 2034. Aramchol meglumine circulates in the blood as Aramchol.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Aramchol meglumine is an improved compound using a salt form of Aramchol that has significantly greater water solubility than the free acid and an NCE patent protection valid until December 2034.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
Galmed Pharmaceuticals' lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2021
Details:
The symposium will primarily focus on Aramchol, currently in Phase 3 for non-alcoholic steatohepatitis (NASH) and liver fibrosis, and Amilo-5MER for chronic inflammatory disorders.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
ASC41 is an oral thyroid hormone receptor beta agonist and Aramchol is a novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, linked by a stable amide group. The team will work together combining both the therapies for the treatment of NASH.
Lead Product(s): ASC41,Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC41
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galmed Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
